Does Blue Cross Blue Shield of Illinois Cover Farxiga?

How BCBSIL Formulary Placement Works for Farxiga

Blue Cross Blue Shield of Illinois organizes prescription drugs into a tiered formulary system that determines patient cost-sharing. Farxiga appears on most BCBSIL commercial formularies as a Tier 3 preferred brand medication, though specific placement varies by plan type and employer group.

BCBSIL operates multiple formulary lists depending on the product line. The Blue Choice PPO, Blue Advantage HMO, and marketplace (ACA) plans each maintain separate drug lists updated quarterly. According to the BCBSIL formulary search tool, Farxiga's placement shifted from Tier 4 to Tier 3 on several plan types beginning in 2024, reflecting the drug's expanded FDA indications beyond diabetes alone. The SGLT2 inhibitor class gained formulary preference after the FDA approved dapagliflozin for chronic kidney disease in April 2021 and heart failure with preserved ejection fraction in 2023, based on results from the DAPA-CKD trial (N=4,304), which demonstrated a 39% relative risk reduction in the composite of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death.

For employer-sponsored plans, formulary placement depends on the specific benefits package the employer selected. Large self-insured groups may negotiate custom formularies that place Farxiga differently than BCBSIL's standard lists. Patients should verify coverage through the member portal or by calling the number on the back of their insurance card.

Prior Authorization Requirements

BCBSIL requires prior authorization for Farxiga across most plan types. This is standard practice for branded SGLT2 inhibitors.

The prior authorization criteria typically require documentation of the following: a confirmed diagnosis of type 2 diabetes mellitus, NYHA Class II-IV heart failure, or chronic kidney disease with eGFR 25-75 mL/min/1.73m²; for the diabetes indication, evidence of a prior trial of metformin (minimum 3 months) unless contraindicated; current A1C level within the past 90 days; and prescriber attestation that the patient has no history of diabetic ketoacidosis or severe recurrent genitourinary infections. The American Diabetes Association Standards of Care 2024 recommend SGLT2 inhibitors as second-line therapy after metformin for patients with established atherosclerotic cardiovascular disease, heart failure, or CKD, which forms the clinical basis for most insurer step-therapy requirements.

Processing time for standard prior authorization requests is 5-7 business days. Urgent requests receive 24-72 hour turnaround. Electronic prior authorization (ePA) submitted through the prescriber's EHR system typically processes faster than fax-based submissions.

Cost-Sharing by Plan Type

What patients actually pay for Farxiga varies substantially across BCBSIL plan categories. The differences can amount to hundreds of dollars annually.

On BCBSIL commercial PPO plans with standard cost-sharing, Tier 3 drugs carry a copay of $35 to $60 per 30-day supply after the deductible is met. High-deductible health plans (HDHPs) paired with HSAs require the full negotiated rate (often $400-$500) until the deductible is satisfied, after which coinsurance of 20-30% applies. BCBSIL marketplace (ACA) Silver plans typically assign Farxiga a $75-$90 copay, while Gold plans reduce this to $45-$65.

For BCBSIL Medicare Advantage Part D enrollees, Farxiga falls under the standard Part D benefit structure. During the initial coverage phase (after the $545 deductible in 2025), patients pay 25% coinsurance for Tier 3 drugs. Once total drug costs reach $5,030, the catastrophic phase begins with maximum copays of $35 for brand drugs per the Inflation Reduction Act provisions. The $2,000 annual out-of-pocket cap on Part D spending, fully effective as of 2025, means no Medicare Advantage enrollee pays more than $2,000 total for all covered prescriptions in a calendar year.

According to the DECLARE-TIMI 58 trial (N=17,160), dapagliflozin reduced hospitalization for heart failure by 27% (HR 0.73 to 95% CI 0.61-0.88) in patients with type 2 diabetes and multiple cardiovascular risk factors. This cardiovascular benefit data has driven expanded coverage for the drug across major insurers including BCBSIL.

The Step Therapy Process

Step therapy (also called "fail first") is BCBSIL's requirement that patients try less expensive medications before the insurer approves a costlier option. For Farxiga prescribed for type 2 diabetes, this typically means documented use of metformin.

The step therapy protocol for SGLT2 inhibitors at BCBSIL generally requires: 90 days of metformin at maximum tolerated dose (up to 2 to 000 mg daily), OR documentation of metformin intolerance or contraindication (eGFR <30 mL/min/1.73m², GI intolerance despite extended-release formulation, vitamin B12 deficiency attributed to metformin). If the prescriber documents that the patient has established heart failure or CKD Stage 3-4, step therapy through metformin may be waived because the 2022 AHA/ACC/HFSA Guideline for Management of Heart Failure recommends SGLT2 inhibitors as first-line therapy for HFrEF regardless of diabetes status.

Dr. Mikhail Kosiborod, a cardiologist and principal investigator of the DELIVER trial, stated: "SGLT2 inhibitors have moved beyond their diabetes origins. They are now a cornerstone of heart failure therapy independent of glycemic status." This shift in clinical positioning influences how insurers handle step therapy exemptions.

Patients with a primary diagnosis of heart failure (ICD-10 codes I50.x) or CKD (N18.x) rather than type 2 diabetes (E11.x) may bypass the metformin step entirely. The prescribing physician should clearly document the primary indication on the prior authorization form.

How to Appeal a Denial

If BCBSIL denies coverage for Farxiga, patients and prescribers have structured appeal rights under Illinois insurance law. Approximately 40-60% of prior authorization denials for SGLT2 inhibitors are overturned on first-level appeal when supported by adequate clinical documentation.

The appeal process has three levels. First-level internal appeal must be filed within 180 days of the denial notice. The appeal should include: a letter of medical necessity from the prescribing physician citing specific guideline recommendations, relevant lab results (A1C, eGFR, BNP/NT-proBNP for heart failure), documentation of prior medication trials and their outcomes, and any relevant specialist consultation notes. Second-level internal appeal follows if the first is denied. External independent review through the Illinois Department of Insurance becomes available after exhausting internal appeals.

Key documentation that strengthens appeals includes citing the DAPA-HF trial (N=4,744), which showed dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74 to 95% CI 0.65-0.85) regardless of diabetes status. For CKD-related appeals, the DAPA-CKD data showing a 44% reduction in sustained eGFR decline provides strong clinical justification.

Illinois Administrative Code Title 50, Section 5402 requires that insurers provide written explanation of denial rationale and specific criteria not met. This transparency requirement gives prescribers a roadmap for addressing the exact clinical gap in their appeal documentation.

AstraZeneca Savings Programs

The manufacturer offers multiple programs to reduce Farxiga out-of-pocket costs for BCBSIL members. These programs operate independently of insurance coverage decisions.

The Farxiga Savings Card reduces copays to as low as $0 per month for commercially insured patients, with a maximum annual benefit of $3,400. This card cannot be used by patients enrolled in Medicare, Medicaid, or other federal healthcare programs due to the Anti-Kickback Statute. Eligibility requires active commercial insurance coverage for Farxiga; the card covers the difference between the patient's copay/coinsurance and $0.

AstraZeneca's patient assistance program (AZ&Me) provides free Farxiga to uninsured patients or those who have been denied coverage and earn below 400% of the federal poverty level. Applications require income documentation and a signed prescription from the treating physician. Processing takes 4-6 weeks from completed application submission.

For BCBSIL members on high-deductible plans who face the full retail price during the deductible phase, the savings card can reduce their cost from approximately $580 to $0, making the deductible period financially manageable. The card resets annually each January.

Farxiga vs. Other SGLT2 Inhibitors on BCBSIL Formularies

BCBSIL's formulary positioning of Farxiga relative to other SGLT2 inhibitors affects prescribing decisions. Understanding the competitive formulary placement helps patients and prescribers identify the most cost-effective option.

Jardiance (empagliflozin) often shares the same tier as Farxiga on BCBSIL formularies, though some plan variants prefer one over the other. The EMPA-REG OUTCOME trial (N=7,020) demonstrated empagliflozin reduced cardiovascular death by 38% in patients with type 2 diabetes and established CVD. Both drugs carry similar formulary positioning because both have strong cardiovascular and renal outcome data.

Invokana (canagliflozin) sits on Tier 4 (non-preferred brand) on many BCBSIL plans following safety signals around amputation risk identified in the CANVAS program, despite subsequent data suggesting this risk may not be a class effect. Steglatro (ertugliflozin) has limited formulary coverage after the VERTIS CV trial showed no superiority over placebo for its primary cardiovascular endpoint.

When BCBSIL designates Jardiance as preferred over Farxiga (or vice versa), switching between the two SGLT2 inhibitors is clinically reasonable for most patients. Both dapagliflozin 10 mg and empagliflozin 10 mg produce approximately 0.5-0.7% A1C reduction, 2-3 kg weight loss, and 4-5 mmHg systolic blood pressure lowering per the 2024 ADA Standards of Care. The prescriber can request a formulary exception if clinical reasons favor Farxiga specifically (e.g., CKD indication where DAPA-CKD data is stronger than available empagliflozin renal data).

Medicare Advantage Specific Considerations

BCBSIL Medicare Advantage plans have distinct formulary rules, quantity limits, and coverage determination processes compared to commercial plans. Over 400,000 Illinois residents are enrolled in BCBSIL Medicare Advantage products.

Medicare Part D formularies must cover at least two drugs in each pharmacologic class per CMS formulary review guidelines. SGLT2 inhibitors are covered under the antidiabetic class. BCBSIL Medicare Advantage typically covers Farxiga with a quantity limit of 30 tablets per 30 days (one daily). The Inflation Reduction Act's $35 monthly insulin cap does not apply to SGLT2 inhibitors, but the $2,000 annual out-of-pocket maximum does cap total prescription spending.

Medicare Advantage members cannot use manufacturer copay cards. However, the Medicare Part D Low-Income Subsidy (LIS/Extra Help) reduces Farxiga copays to $4.50 (generic) or $11.20 (brand) per prescription for qualifying enrollees with income below 150% of the federal poverty level. Partial LIS benefits are available up to certain income thresholds.

Coverage determinations for Medicare Advantage plans follow CMS timelines: standard decisions within 72 hours, expedited decisions within 24 hours. The prescriber must attest that waiting for a standard determination could jeopardize the patient's life, health, or ability to regain maximum function to qualify for expedited review.

Clinical Evidence Supporting Coverage

The strength of Farxiga's clinical trial portfolio directly influences BCBSIL's formulary decisions. Drugs with cardiovascular and renal outcome benefits receive preferential placement because they reduce downstream hospitalization costs.

Three landmark trials form the coverage justification. DECLARE-TIMI 58 (N=17,160) established cardiovascular safety and showed reduced heart failure hospitalization. DAPA-HF (N=4,744) proved benefit in heart failure with reduced ejection fraction. DAPA-CKD (N=4,304) demonstrated renal protection across diabetic and non-diabetic CKD. Collectively, these trials enrolled over 26,000 patients and established dapagliflozin as effective across three distinct disease states.

Dr. David Cherney, a nephrologist at the University of Toronto and DAPA-CKD investigator, noted: "The renal protective effects of dapagliflozin were consistent across patients with and without diabetes, fundamentally changing how we approach CKD treatment." This cross-indication efficacy drove the FDA's expanded label and subsequently broadened insurer coverage beyond diabetes-only formulary placement.

The 2024 KDIGO Clinical Practice Guideline for CKD recommends SGLT2 inhibitors for all patients with CKD and eGFR ≥20 mL/min/1.73m² regardless of diabetes status, providing guideline-level support for coverage requests in non-diabetic kidney disease patients.

Illinois-Specific Insurance Regulations

Illinois insurance law provides additional patient protections that affect how BCBSIL handles Farxiga coverage decisions. State-level mandates supplement federal requirements.

The Illinois Insurance Code (215 ILCS 5/) requires health insurers to maintain adequate prescription drug coverage and prohibits arbitrary formulary exclusions of entire drug classes. The Illinois Department of Insurance oversees external review processes and has authority to mandate coverage when an insurer's denial is found unreasonable. Illinois also participates in the NAIC model for step-therapy exception processes, requiring insurers to grant exceptions when: the required first-step drug is contraindicated, previously caused an adverse reaction, is expected to be ineffective based on the patient's clinical history, or the patient is stable on the requested medication.

For patients switching to BCBSIL from another insurer where Farxiga was previously covered, Illinois continuity of care provisions may allow temporary coverage (typically 90 days) without new prior authorization while the transition occurs. This prevents treatment interruptions during open enrollment plan changes.

BCBSIL must also comply with the federal Mental Health Parity and Addiction Equity Act and the Affordable Care Act's essential health benefits requirements, though these primarily affect coverage breadth rather than individual drug-level formulary placement. The practical impact for Farxiga patients is that BCBSIL cannot impose more restrictive utilization management on diabetes medications than it applies to medical/surgical benefits of equivalent cost.